Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GVXN SD133
- Development stage
- Phase 1
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GVXN SD133 is a monovalent bioconjugate vaccine candidate designed to prevent infections caused by *Shigella dysenteriae* type 1. Developed by GlycoVaxyn (now a subsidiary of GSK), the vaccine utilizes a proprietary bioconjugation platform where the *S. dysenteriae* O1 lipopolysaccharide (LPS) O-antigen is enzymatically linked to a carrier protein, typically the *Pseudomonas aeruginosa* Exoprotein A (EPA), within engineered *Escherichia coli* cells. This approach aims to overcome the limitations of traditional chemical conjugation by ensuring a more consistent and defined product. The vaccine is intended to elicit high titers of functional antibodies against the O-antigen, providing protection against bacillary dysentery. While it successfully completed Phase 1 clinical testing, development of this specific monovalent asset has been superseded by multivalent Shigella vaccine programs within the GSK pipeline.
- Brand names
- GVXN SD133
- Other names
- Shigella dysenteriae bioconjugate vaccineShigella dysenteriae O1 bioconjugate vaccineGVXN-SD133GVXN-SD-133GVXN-SD 133
02
Targets
S. dysenteriae O1 polysaccharide (Shigella dysenteriae serotype 1 O-polysaccharide)
Beyond the preview
Go deeper on GVXN SD133.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GVXN SD133.